A BETTER APPROACH,
FOR BETTER BREAST CANCER TRIALS.
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
PRE-CONFIGURED SOLUTION
BREAST CANCER OVERVIEW
Signant's Breast Cancer Experience in the Past 5 Years
Enhance Your Breast Cancer Trial Solutions with Signant
CONNECT WITH US
Breast cancer affects more women worldwide than any other cancer. Despite its prevalence, studying and improving treatment is extremely complex. Oncology studies often involve multiple cohorts, tumor types, scattered sites, and expensive medications. More importantly, breast cancer patients face debilitating symptoms that can make participation in studies difficult.
That’s where Signant Health’s SmartSignals™ evidence generation solutions can help.
IMPLEMENT eCOA IN JUST 8 WEEKS
PLACE THE PATIENT FIRST
GAIN RICHER INSIGHTS
SIMPLIFY THE CONSENT PROCESS
OPTIMIZE SUPPLY MANAGEMENT
DIGITALIZE THE ENTIRE PROCESS
With over 20 years of experience supporting breast cancer trials, we created a pre-configured eCOA solution that incorporates pre-validated library instruments, scientific design best practices, oncology-specific features as well as our unrivaled global logistics and support.
Our patient-focused approach is embedded in everything from the software to the eCOA instruments’ overall designs. For example, thoughtfully migrating instrument layouts to electronic formats to ensure ease of use, such as larger, well-spaced buttons compensate for treatment-related finger numbness.
It’s 33% faster than other eCOA options and will reduce your costs by 20%.
With our sensors and wearables, you can collect objective data on sleep and activity patterns, for enhanced insight into the post-treatment recovery associated with each treatment cycle. Pair with our eCOA for a continuous, real-time view of each patients’ health status.
Signant Health’s SmartSignals™ eConsent uses engaging multimedia to convey complex information and allows patients to flag sections they have questions on. The solution also handles the multiple consents and protocol amendments common in breast cancer trials, limiting the risk of inspection findings.
Our SmartSignals™ RTSM solution uses proprietary algorithms to optimize drug supplies for the different, complex study designs associated with breast cancer trials, and applies randomization adaptations seamlessly.
While all of our solutions can be used as standalone tools, they seamlessly integrate with one another to further enhance the accuracy and efficiency of your breast cancer study.
BILL BYROM, PhD
TODD EVERHART, MD
FLORENCE MOWLEM, PhD
Dr. Byrom has worked in the Pharmaceutical industry for 30 years and is the author of over 70 publications and two industry textbooks on electronic patient-reported outcomes (ePRO).
Dr. Everhart is board-certified in internal medicine and a fellow of the American College of Physicians with over 23 years of experience in the practice of medicine and over 12 years of experience in clinical development.
Dr. Mowlem works across therapeutic areas and is also the eCOA Science Oncology lead; her most recent scientific work includes understanding how the unique needs of oncology patients can impact their use of electronic devices in oncology trials.
VP Product Intelligence & Positioning
Clinical VP Internal Medicine
Scientific Advisor
Breast Cancer Trial Solutions Resources
MEET THE EXPERTS
Discuss your next breast cancer trial with our subject matter experts, and we’ll tailor our eCOA solution to fit your needs.
